Home › Crohn's Disease › Massachusetts › Newton
Crohn's Disease clinical trials in Newton, MA
3 studies for Crohn's Disease are looking for participants at sites in and around Newton (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
RecruitingPhase 4
- Gastro Health Research - Framingham, Framingham · 11 mi away
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
RecruitingPhase 3
- Massachusetts General Hospital - Mass General Waltham /ID# 255767, Waltham · 3 mi away
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
RecruitingPhase 3
- Massachusetts General Hospital, Waltham · 3 mi away
About Crohn's Disease
Crohn's Disease can cause inflammation in any area from the mouth to the anus. Read about medicines, surgery or dietary management to treat symptoms.
More about Crohn's Disease on MedlinePlus
Crohn's Disease trials in other cities
- New York City, NY35 studies
- Cleveland, OH19 studies
- St. Louis, MO19 studies
- Boston, MA19 studies
- Miami, FL19 studies
- Orlando, FL17 studies
- Houston, TX17 studies
- Atlanta, GA17 studies
- Tyler, TX16 studies
- San Diego, CA15 studies
- San Antonio, TX15 studies
- Los Angeles, CA15 studies
Other studies in Newton
- Alzheimer's Disease12 studies
- Major Depressive Disorder10 studies
- Obesity9 studies
- Depression7 studies
- Psoriasis6 studies
- Overweight6 studies
- Non-Small Cell Lung Cancer5 studies
- Atopic Dermatitis (Eczema)4 studies
- Schizophrenia4 studies
- Breast Cancer4 studies
- Cancer (all types)4 studies
- Mild Cognitive Impairment4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.